losartan has been researched along with Hypertension, Malignant in 3 studies
Losartan: An antagonist of ANGIOTENSIN TYPE 1 RECEPTOR with antihypertensive activity due to the reduced pressor effect of ANGIOTENSIN II.
losartan : A biphenylyltetrazole where a 1,1'-biphenyl group is attached at the 5-position and has an additional trisubstituted imidazol-1-ylmethyl group at the 4'-position
Hypertension, Malignant: A condition of markedly elevated BLOOD PRESSURE with DIASTOLIC PRESSURE usually greater than 120 mm Hg. Malignant hypertension is characterized by widespread vascular damage, PAPILLEDEMA, retinopathy, HYPERTENSIVE ENCEPHALOPATHY, and renal dysfunction.
| Excerpt | Relevance | Reference |
|---|---|---|
| "We investigated the role of angiotensin II and endothelin-1 using the angiotensin AT1 receptor antagonist losartan and the endothelin ETA receptor antagonist atrasentan, in malignant hypertension and renal failure and damage induced by nitric oxide (NO) synthase inhibition in Harlan Sprague-Dawley (SD) rats." | 3.75 | Protective effects of angiotensin AT1 receptor blockade in malignant hypertension in the rat. ( Agharazii, M; Bélanger, S; Larivière, R; Lebel, M; Lemieux, P; Therrien, F, 2009) |
| "The blood pressure was decreased after chronic treatment with enalapril, MK-954, and hydralazine in deoxycorticosterone acetate (DOCA)-salt-induced malignant hypertension of spontaneously hypertensive rats (SHR); however, ventricular weight and plasma brain natriuretic peptide (BNP) concentration were decreased after enalapril and MK-954 but not after hydralazine." | 3.69 | Cardiac hypertrophy and brain natriuretic peptide in experimental hypertension. ( Fukui, T; Horio, T; Kohno, M; Kurihara, N; Takeda, T; Yasunari, K; Yokokawa, K; Yoshiyama, M, 1994) |
| "Treatment with losartan completely prevented the impaired autoregulation and pressure-natriuresis relationship as well as the development of hypertension in I3C-induced rats." | 1.37 | Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats. ( Cervenka, L; Chábová, VC; Hammock, BD; Honetschlägerová, Z; Husková, Z; Hwang, SH; Imig, JD; Kopkan, L; Kramer, HJ; Kujal, P; Sporková, A; Tesař, V; Vernerová, Z, 2011) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 1 (33.33) | 18.2507 |
| 2000's | 1 (33.33) | 29.6817 |
| 2010's | 1 (33.33) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Therrien, F | 1 |
| Lemieux, P | 1 |
| Bélanger, S | 1 |
| Agharazii, M | 1 |
| Lebel, M | 1 |
| Larivière, R | 1 |
| Honetschlägerová, Z | 1 |
| Sporková, A | 1 |
| Kopkan, L | 1 |
| Husková, Z | 1 |
| Hwang, SH | 1 |
| Hammock, BD | 1 |
| Imig, JD | 1 |
| Kramer, HJ | 1 |
| Kujal, P | 1 |
| Vernerová, Z | 1 |
| Chábová, VC | 1 |
| Tesař, V | 1 |
| Cervenka, L | 1 |
| Kohno, M | 1 |
| Fukui, T | 1 |
| Horio, T | 1 |
| Yokokawa, K | 1 |
| Yasunari, K | 1 |
| Yoshiyama, M | 1 |
| Kurihara, N | 1 |
| Takeda, T | 1 |
3 other studies available for losartan and Hypertension, Malignant
| Article | Year |
|---|---|
Protective effects of angiotensin AT1 receptor blockade in malignant hypertension in the rat.
Topics: Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Animals; Antihypertensive Agents; Atrasenta | 2009 |
Inhibition of soluble epoxide hydrolase improves the impaired pressure-natriuresis relationship and attenuates the development of hypertension and hypertension-associated end-organ damage in Cyp1a1-Ren-2 transgenic rats.
Topics: Angiotensin II Type 1 Receptor Blockers; Animals; Blood Pressure; Cytochrome P-450 CYP1A1; Disease M | 2011 |
Cardiac hypertrophy and brain natriuretic peptide in experimental hypertension.
Topics: Animals; Atrial Natriuretic Factor; Biphenyl Compounds; Blood Pressure; Blood Urea Nitrogen; Cardiom | 1994 |